ArticleJACC. Case reports2026
Transapical Edge-to-Edge Repair for Systolic Anterior Motion in Obstructive Hypertrophic Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transapical mitral valve edge-to-edge repair (TA-TEER) offers a therapeutic option for obstructive hypertrophic cardiomyopathy with severe mitral regurgitation and systolic anterior motion. In this case series, we present 3 elderly patients with obstructive hypertrophic cardiomyopathy who underwent TA-TEER after declining conventional surgical options. Patient 1: A 66-year-old woman achieved immediate resolution of mitral regurgitation and systolic anterior motion, but developed hemolysis and hypotension at 2 weeks, requiring mechanical valve replacement. Patient 2: A 65-year-old man showed sustained improvement with resolved mitral regurgitation and systolic anterior motion at 4-month follow-up. Patient 3: A 70-year-old woman demonstrated immediate resolution with stable results. TA-TEER successfully addressed mitral regurgitation and systolic anterior motion in all cases, though 1 patient experienced serious complications requiring reoperation. Although TA-TEER may serve as a salvage option for high-risk patients, careful patient selection and awareness of potential complications are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.